Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;14(21):2161-2177.
doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7.

An overview of meningiomas

Robin A Buerki  1 , Craig M Horbinski  2   3 , Timothy Kruser  3   4 , Peleg M Horowitz  5 , Charles David James  3   6 , Rimas V Lukas  3   7
Affiliations
Review

An overview of meningiomas

Robin A Buerki et al. Future Oncol. 2018 Sep.

Abstract

Meningiomas are the most common primary intracranial tumor. Important advances are occurring in meningioma research. These are expected to accelerate, potentially leading to impactful changes on the management of meningiomas in the near and medium term. This review will cover the histo- and molecular pathology of meningiomas, including recent 2016 updates to the WHO classification of CNS tumors. We will discuss clinical and radiographic presentation and therapeutic management. Surgery and radiotherapy, the two longstanding primary therapeutic modalities, will be discussed at length. In addition, data from prior and ongoing investigations of other treatment modalities, including systemic and targeted therapies, will be covered. This review will quickly update the reader on the contemporary management and future directions in meningiomas. [Formula: see text].

Keywords: chemotherapy; imaging; meningioma; molecular pathology; mutations; radiotherapy; stereotactic radiosurgery; surgery; targeted therapy; tumor treating fields.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work is supported by P50CA221747 SPORE for Translational Approaches to Brain Cancer (CM Horbinski, CD James, RV Lukas). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. MRI of convexity meningioma.
Coronal T1 postcontrast MRI images demonstrating a large convexity meningioma compressing underlying brain. The tumor arises from the dura  is homogenously enhancing and distinct from the underlying brain. (A) Postcontrast images demonstrating subsequent resection of the tumor and (B) the postcontrast enhancement of the dura most likely represents postoperative changes, however, residual tumor cannot be ruled out.
<b>Figure 2.</b>
Figure 2.. Histologic features of WHO grade I–III meningiomas.
(A) Grade I tumors typically contain numerous whorls of meningothelial cells (black arrow), with varying stages of maturation into mineralized psammoma bodies (white arrow). (B) Nuclear clearing (black arrows) and intranuclear cytoplasmic pseudoinclusions (white arrow) are common in grade I tumors, but mitoses and large nucleoli are not. (C) Invasion into the underlying brain (black arrow) is a feature of many grade II meningiomas. (D) Four to 19 mitoses per ten high-power fields (black arrow) and prominent nucleoli (white arrow) are also seen in grade II tumors. (E) Grade III meningiomas usually show increased cellularity and micronecrotic foci (black arrows) and (F) such tumors have 20 or more mitoses per ten high-power fields (black arrows). Scale bar in F = 120 μm in (A) and (C), 300 μm in (E) and 30 μm in (B), (D) and (F).
<b>Figure 3.</b>
Figure 3.. European association of neuro-oncology guidelines for evaluation and treatment of meningioma.
See this image and copyright information in PMC

References

    1. Chamberlain MC. Meningiomas. In: Norden AD, Reardon DA, Wen PCY, editors. Primary Central Nervous System Tumors: Pathogenesis and Therapy. Humana Press; NJ, USA: 2011. pp. 355–375.
    1. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-oncology. 2016;18(Suppl. 5):v1–v75. - PMC - PubMed

    2. •• Epidemiology of primary CNS tumors including meningiomas.

    1. Central Brain Tumor Registry of the United States (CBTRUS) Primary brain tumors in the United States statistical report 1998–2002. 2005 www.cbtrus.org/reports/2005-2006/2006report.pdf
    1. Hatch EE, Linet MS, Zhang J, et al. Reproductive and hormonal factors and risk of brain tumors in adult females. Int. J. Cancer. 2005;114(5):797–805. - PubMed
    1. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol. 2010;99(3):307–314. - PMC - PubMed

LinkOut - more resources